CHD1 deletion stabilizes HIF1a to promote angiogenesis and glycolysis in prostate cancer

被引:3
|
作者
Wang, Yu-Zhao [1 ]
Qian, Yu-Chen [1 ]
Yang, Wen-Jie [1 ]
Ye, Lei-Hong [1 ]
Guo, Guo-Dong [1 ]
Lv, Wei [1 ]
Huan, Meng-Xi [1 ]
Feng, Xiao-Yu [1 ]
Wang, Ke [1 ]
Yang, Zhao [1 ,2 ]
Gao, Yang [1 ,2 ]
Li, Lei [1 ,2 ]
Chen, Yu-Le [1 ,2 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Urol, Xian 710061, Peoples R China
[2] Minist Educ, Oncol Res Lab, Key Lab Environm & Genes Related Dis, Xian 710061, Peoples R China
基金
中国国家自然科学基金;
关键词
angiogenesis; CHD1; HIF1a; metabolism; prostate cancer; PROLYL HYDROXYLASES; TUMOR HYPOXIA; CHROMATIN; EXPRESSION; THERAPY; PTEN;
D O I
10.4103/aja202287
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Chromodomain-helicase-DNA-binding protein 1 (CHD1) deletion is among the most common mutations in prostate cancer (PCa), but its role remains unclear. In this study, RNA sequencing was conducted in PCa cells after clustered regularly interspaced palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9)-based CHD1 knockout. Gene set enrichment analysis (GSEA) indicated upregulation of hypoxia-related pathways. A subsequent study confirmed that CHD1 deletion significantly upregulated hypoxia-inducible factor 1 alpha (HIF1 alpha) expression. Mechanistic investigation revealed that CHD1 deletion upregulated HIF1 alpha by transcriptionally downregulating prolyl hydroxylase domain protein 2 (PHD2), a prolyl hydroxylase catalyzing the hydroxylation of HIF1 alpha and thus promoting its degradation by the E3 ligase von Hippel-Lindau tumor suppressor (VHL). Functional analysis showed that CHD1 deletion promoted angiogenesis and glycolysis, possibly through HIF1 alpha target genes. Taken together, these findings indicate that CHD1 deletion enhances HIF1 alpha expression through PHD2 downregulation and therefore promotes angiogenesis and metabolic reprogramming in PCa.
引用
收藏
页码:152 / 157
页数:6
相关论文
共 50 条
  • [1] Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness
    S Huang
    Z G Gulzar
    K Salari
    J Lapointe
    J D Brooks
    J R Pollack
    Oncogene, 2012, 31 : 4164 - 4170
  • [2] Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness
    Huang, S.
    Gulzar, Z. G.
    Salari, K.
    Lapointe, J.
    Brooks, J. D.
    Pollack, J. R.
    ONCOGENE, 2012, 31 (37) : 4164 - 4170
  • [3] CHD1 Deletion in a Cohort of Castration-Resistant Prostate Cancer
    Friedman, C. S.
    Deng, F-M
    Barbieri, C. E.
    MacDonald, T.
    Xu, W.
    Melamed, J.
    Rubin, M. A.
    Mosquera, J. M.
    Zhou, M.
    MODERN PATHOLOGY, 2014, 27 : 230A - 230A
  • [4] CHD1 Deletion in a Cohort of Castration-Resistant Prostate Cancer
    Friedman, C. S.
    Deng, F-M
    Barbieri, C. E.
    MacDonald, T.
    Xu, W.
    Melamed, J.
    Rubin, M. A.
    Mosquera, J. M.
    Zhou, M.
    LABORATORY INVESTIGATION, 2014, 94 : 230A - 230A
  • [5] CHD1, a multifaceted epigenetic remodeler in prostate cancer
    Li, Haoyan
    Gigi, Loraine
    Zhao, Di
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] Monitoring CHD1 During Prostate Cancer Progression
    Rodrigues, Daniel Nava
    Boysen, Gunther
    Mateo, Joaquin
    Christova, Rossitza
    Riisnaes, Ruth
    Crespo, Mateus
    MacDonald, Theresa Y.
    Miranda, Susana A. A.
    Figueiredo, Ines
    Gil, Veronica
    Aziz, Sara
    Mehra, Niven
    Sharp, Adam
    Rescigno, Pasquale
    Mosquera, Juan Miguel
    Barbieri, Christopher E.
    Rubin, Mark
    De Bono, Johann S.
    LABORATORY INVESTIGATION, 2016, 96 : 251A - 251A
  • [7] Monitoring CHD1 During Prostate Cancer Progression
    Rodrigues, Daniel Nava
    Boysen, Gunther
    Mateo, Joaquin
    Christova, Rossitza
    Riisnaes, Ruth
    Crespo, Mateus
    MacDonald, Theresa Y.
    Miranda, Susana A. A.
    Figueiredo, Ines
    Gil, Veronica
    Aziz, Sara
    Mehra, Niven
    Sharp, Adam
    Rescigno, Pasquale
    Mosquera, Juan Miguel
    Barbieri, Christopher E.
    Rubin, Mark
    De Bono, Johann S.
    MODERN PATHOLOGY, 2016, 29 : 251A - 251A
  • [8] Monitoring CHD1 during prostate cancer progression
    Boysen, Gunther
    Rodrigues, Daniel Nava
    Mateo, Joaquin
    Christova, Rossitza
    Riisnaes, Ruth
    Crespo, Mateus
    MacDonald, Theresa
    Miranda, Susana
    Figueiredo, Ines
    Aziz, Veronica Gil Sara
    Sharp, Adam
    Mehra, Niven
    Rescigno, Pasquale
    Mosquera, Juan M.
    Barbieri, Christopher E.
    Rubin, Mark A.
    de Bono, Johann S.
    CANCER RESEARCH, 2016, 76
  • [9] CHD1 as a therapeutic target for prostate cancer.
    Wang, Y. Alan
    Zhao, Di
    Depinho, Ron
    CANCER RESEARCH, 2018, 78 (16) : 79 - 80
  • [10] Coordinated roles of CHD1 and SPOP in prostate cancer pathogenesis
    Vasudevan, Divya
    Blattner, Mirjam
    Deonarine, Lesa D.
    Chen, Yu
    Rubin, Mark A.
    Barbieri, Christopher E.
    CANCER RESEARCH, 2016, 76